Progress in blood pressure control in autosomal dominant polycystic kidney disease

American Journal of Kidney Diseases

Volumn 36, Issue 2, 2000, Pages 266-271

  Ecder, Tevfik ^a   Edelstein, Charles L ^a   Fick Brosnahan, Godela M ^a   Johnson, Ann M ^a   Duley, Irene T ^a   Gabow, Patricia A ^a   Schrier, Robert W ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Autosomal dominant polycystic kidney disease (ADPKD); Blood pressure control; Education; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLOOD PRESSURE REGULATION; EDUCATION PROGRAM; FEMALE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME;

EID: 0034256018     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.8970     Document Type: Article

References (23)

1. Gabow PA, Chapman AB, Johnson AM, Tangel DJ, Duley IT, Kaehny WD, Manco-Johnson M, Schrier RW: Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38:1177-1180,1990
2. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease. Kidney Int 41:1311 -1319,1992
3. Marcelli D, Locatelli F, Albert! D, Graziani G, Buccianti G, Redaelli B, Giangrande A, and the Northern Italian Cooperative Study Group: Hypertension as a factor in chronic renal insufficiency progression in polycystic kidney disease. Nephrol Dial Transplant 10:S15-S17, 1995(suppl 6)
4. Chapman AB, Schrier RW: Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol 11:653-660, 1991
5. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW: Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8:1292-1297,1997
6. Pick GM, Johnson AM, Hammond WS, Gabow PA: Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:2048-2056,1995
7. The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
8. Cockcroft SW, Gault HM: Prediction of creatinine clearances from serum creatinine. Nephron 16:31-41, 1976
9. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension 26:60-69, 1995
10. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25:305-313,1995
11. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P: Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 10:1097-1102, 1997
12. Colhoun HM, Dong W, Poulter NR: Blood pressure screening, management and control in England: Results from the health survey for England, 1994. J Hypertens 16:747-752, 1998
13. Coca A: Actual blood pressure control: Are we doing things right? J Hypertens 16:S45-S51, 1998 (suppl 1)
14. Chamontin B, Poggi L, Lang T, Menard J, Chevalier H, Gallois H, Crémier O: Prevalence, treatment, and control of hypertension in the French population. Data from a survey on high blood pressure in general practice, 1994. Am J Hypertens 11:759-762,1998
15. Faulhaber H-D, Luft FC: Treatment of high blood pressure in Germany. Am J Hypertens 11:750-753, 1998
16. Hansson L, Zanchetti A, Carruthers SO, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351: 1755-1762, 1998
17. Black DM, Brand RJ, Greenlick M, Hughes G, Smith J, for the SHEP Pilot Research Group: Compliance to treatment for hypertension in elderly patients: The SHEP Pilot Study. J Gerontol 42:552-557, 1987
18. Siegel D, Lopez J: Trends in antihypertensive drug use in the United States. JAMA 278:1745-1748, 1997
19. Chapman AB, Johnson A, Gabow PA, Schrier RW: The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323:1091-1096, 1990
20. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
21. Maschio G, Albert! D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P, and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting enzyme inhibitors on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
22. Giatras I, Lau J, Levey AS, for the AngiotensinConverting-Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 127:337-345,1997
23. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 349:1857-1863, 1997